Literature DB >> 7532293

Direct binding of eps8 to the juxtamembrane domain of EGFR is phosphotyrosine- and SH2-independent.

P Castagnino1, Z Biesova, W T Wong, F Fazioli, G N Gill, P P Di Fiore.   

Abstract

Several signal transducers bind through their SH2 domains to phosphotyrosine-containing motifs present in receptor tyrosine kinases (RTKs). However, the juxtamembrane regions of the epidermal growth factor receptor (EGFR) and of the related erbB-2 protein, while important in mitogenic signaling, lack demonstrable tyrosine phosphorylation sites, suggesting that other modalities of receptor-transducer interactions exist. A candidate for investigating this type of association is p97eps8, a recently described substrate for RTKs. p97eps8 is phosphorylated by several RTKs, associates with EGFR in vivo and, upon overexpression, enhances the transduction of EGFR-mediated mitogenic signals. Here we report that eps8 binds directly to the juxtamembrane region of EGFR through a domain that does not bear resemblance to SH2 domains and by a mechanism that does not require the presence of phosphotyrosine residues. Thus, the physical association between EGFR and eps8 represents a novel interaction between RTKs and their substrates.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7532293

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  14 in total

1.  EPS8 upregulates FOXM1 expression, enhancing cell growth and motility.

Authors:  Huixin Wang; Muy-Teck Teh; Youngmi Ji; Vyomesh Patel; Shahrzad Firouzabadian; Anisha A Patel; J Silvio Gutkind; W Andrew Yeudall
Journal:  Carcinogenesis       Date:  2010-03-29       Impact factor: 4.944

2.  A RhoA and Rnd3 cycle regulates actin reassembly during membrane blebbing.

Authors:  Kana Aoki; Fumiyo Maeda; Tomoya Nagasako; Yuki Mochizuki; Seiichi Uchida; Junichi Ikenouchi
Journal:  Proc Natl Acad Sci U S A       Date:  2016-03-14       Impact factor: 11.205

3.  Constitutive phosphorylation of eps8 in tumor cell lines: relevance to malignant transformation.

Authors:  B Matoskova; W T Wong; A E Salcini; P G Pelicci; P P Di Fiore
Journal:  Mol Cell Biol       Date:  1995-07       Impact factor: 4.272

4.  A comprehensive pathway map of epidermal growth factor receptor signaling.

Authors:  Kanae Oda; Yukiko Matsuoka; Akira Funahashi; Hiroaki Kitano
Journal:  Mol Syst Biol       Date:  2005-05-25       Impact factor: 11.429

5.  Interaction of the PA2G4 (EBP1) protein with ErbB-3 and regulation of this binding by heregulin.

Authors:  J Y Yoo; X W Wang; A K Rishi; T Lessor; X M Xia; T A Gustafson; A W Hamburger
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

6.  A synthetic cell-penetrating peptide derived from nuclear localization signal of EPS8 exerts anticancer activity against acute myeloid leukemia.

Authors:  Yiran Chen; Xiaoling Xie; Anqin Wu; Lei Wang; Yuxing Hu; Honghao Zhang; Yuhua Li
Journal:  J Exp Clin Cancer Res       Date:  2018-01-22

7.  A dual-function epidermal growth factor receptor pathway substrate 8 (Eps8)-derived peptide exhibits a potent cytotoxic T lymphocyte-activating effect and a specific inhibitory activity.

Authors:  Xiaoling Xie; Weijun Zhou; Yuxing Hu; Yiran Chen; Honghao Zhang; Yuhua Li
Journal:  Cell Death Dis       Date:  2018-03-07       Impact factor: 8.469

8.  Hnrnpab regulates neural cell motility through transcription of Eps8.

Authors:  Alexa A Lampasona; Kevin Czaplinski
Journal:  RNA       Date:  2018-10-12       Impact factor: 4.942

9.  The cell signaling adaptor protein EPS-8 is essential for C. elegans epidermal elongation and interacts with the ankyrin repeat protein VAB-19.

Authors:  Mei Ding; Ryan S King; Emily C Berry; Ying Wang; Jeff Hardin; Andrew D Chisholm
Journal:  PLoS One       Date:  2008-10-03       Impact factor: 3.240

10.  Epidermal growth factor receptor kinase substrate 8 promotes the metastasis of cervical cancer via the epithelial-mesenchymal transition.

Authors:  Qian Li; Wei Bao; Qiong Fan; Wen-Jing Shi; Zhu-Nan Li; Ying Xu; Dan Wu
Journal:  Mol Med Rep       Date:  2016-08-18       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.